Healthcare Jubilant Life Sciences launches remdesivir in India for treatment of COVID-19 at Rs 4,700 per vial Updated : August 03, 2020 08:42 PM IST The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. JUBI-R will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner, the company said. Subscribe to Moneycontrol PRO at just Rs.33/- per month for the first year. Use code SUPERPRO. Limited period offer. Available on Web and Android.